Loading...
The summary “A New Treatment for Atrial Fibrillation on the Horizon?” — which was published online on September 5, 2007 — contained an error. The second sentence in the second paragraph of the story originally read, “The median time to first recurrence of AF was significantly reduced with dronedarone compared with placebo, as were mean heart rate and reappearance of symptoms during AF recurrence.” The word “reduced” was incorrect as it pertained to median time to first AF recurrence, which was increased with dronedarone. The sentence has been revised to read, “Compared with placebo, dronedarone significantly increased the median time to first recurrence of AF and reduced mean heart rate and reappearance of symptoms during AF recurrence.”
We …